Hepatoid Adenocarcinoma of the Duodenum: An Unusual Location

Ogbonna, Onyekachi Henry; Sakruti, Susmita; Sulieman, Maha; Ali, Ahmed Said; Shokrani, Babak; O'Neal, Patricia

doi:10.1159/000444746

Cited by 13 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most tumors have metastasized at diagnosis with a poor prognosis due to their aggressive behavior (1,2). Hepatoid adenocarcinoma(HAC) has been reported to occur in the stomach (3), esophagus (4,5), duodenum (6), jejunum (2), colon (7), peritoneum (8), pancreas (9)(10)(11)(12)(13), lung (14), ovary (15,16), gallbladder (17), uterus (16,18) and other sites (19). Of these locations, the stomach is the most common site of HAC.…”

Section: Introductionmentioning

confidence: 99%

Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments

et al. 2021

View full text Add to dashboard Cite

Hepatoid adenocarcinoma of the stomach (HAS) is a rare malignant tumor, accounting for only 0.17–15% of gastric cancers. Patients are often diagnosed at an advanced disease stage, and their symptoms are similar to conventional gastric cancer (CGC) without specific clinical manifestation. Morphologically, HAC has identical morphology and immunophenotype compared to hepatocellular carcinoma (HCC). This is considered to be an underestimation in diagnosis due to its rare incidence, and no consensus is reached regarding therapy. HAS generally presents with more aggressive behavior and worse prognosis than CGC. The present review summarizes the current literature and relevant knowledge to elaborate on the epidemic, potential mechanisms, clinical manifestations, diagnosis, management, and prognosis to help clinicians accurately diagnose and treat this malignant tumor.

show abstract

Section: Introductionmentioning

confidence: 99%

Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments

et al. 2021

View full text Add to dashboard Cite

show abstract

“…munohistochemical evidence of hepatocellular differentiation [1]. It most commonly originates in the stomach, but can arise from other organs [2] such as gallbladder [3][4][5], colon [6,7], lungs [8,9], endometrium [10], orbits [11], urinary bladder [12], peritoneal cavity [13], among others.…”

Section: Figure 2: (Left Panel) Sheets Of Tumor Cells Infiltrate the Deep Mucosa; Higher Power (Inset) Shows Abundant Cytoplasm And Occasmentioning

confidence: 99%

Untitled

2021

IJCMCR

View full text Add to dashboard Cite

“…Hepatoid adenocarcinoma is characterized as histologically resembling hepatocellular carcinoma (HCC) with enteroblastic differentiation (1,2). Hepatoid adenocarcinoma has been found in many extrahepatic organs, such as the stomach, ovary, gallbladder, colon, bladder, renal pelvis, lung, duodenum and pancreas, among which the stomach is the most prevalent (3)(4)(5)(6)(7)(8). During the development of the human embryo, both the stomach and liver are primitive foregut derivatives and originate from the endoderm.…”

Section: Introductionmentioning

confidence: 99%

The Value of Perioperative Chemotherapy for Patients With Hepatoid Adenocarcinoma of the Stomach Undergoing Radical Gastrectomy

et al. 2022

View full text Add to dashboard Cite

BackgroundHepatoid adenocarcinoma of the stomach (HAS) is a rare type of gastric cancer, but the role of perioperative chemotherapy is still poorly understood. The aim of this retrospective study was to investigate the associations between perioperative chemotherapy and prognosis of HAS.MethodWe retrospectively analyzed patients with locally advanced HAS who received radical surgery in Peking University Cancer Hospital between November 2009 and October 2020. Patients were divided into neoadjuvant chemotherapy-first (NAC-first) group and surgery-first group. The relationships between perioperative chemotherapy and prognosis of HAS were analyzed using univariate, multivariate survival analyses and propensity score matching analysis (PSM).ResultsA total of 100 patients were included for analysis, including 29 in the NAC-first group and 71 in the surgery-first group. The Her-2 amplification in HAS patients was 22.89% (19/83). For NAC-first group, 4 patients were diagnosed as tumor recession grade 1 (TRG1), 4 patients as TRG 2, and 19 patients as TRG 3. No significant difference in prognosis between the surgery-first group and the NAC-first group (P=0.108) was found using PSM analysis. In the surgery-first group, we found that the survival rate was better in group of ≥6 cycles of adjuvant chemotherapy than that of <6 cycles (P=0.013).ConclusionNAC based on platinum and fluorouracil may not improve the Overall survival (OS) and Disease-free survival time (DFS) of patients with locally advanced HAS. Patients who received ≥6 cycles of adjuvant chemotherapy had better survival. Therefore, the combination treatment of radical gastrectomy and sufficient adjuvant chemotherapy is recommended for patients with locally advanced HAS.

show abstract

Hepatoid Adenocarcinoma of the Duodenum: An Unusual Location

Cited by 13 publications

References 8 publications

Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments

Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments

Untitled

The Value of Perioperative Chemotherapy for Patients With Hepatoid Adenocarcinoma of the Stomach Undergoing Radical Gastrectomy

Contact Info

Product

Resources

About